Skip to content

Efficacy of Bushen Ningxin Decoction combined with Femoston in the treatment of heart-kidney imbalanced Premature Ovarian Insufficiency with circadian rhythm disorder: protocol for a randomized controlled pilot trial

Efficacy of Bushen Ningxin Decoction combined with Femoston in the treatment of heart-kidney imbalanced Premature Ovarian Insufficiency with circadian rhythm disorder: protocol for a randomized controlled pilot trial

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100055043
Enrollment
Unknown
Registered
2021-12-31
Start date
2022-03-01
Completion date
Unknown
Last updated
2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Premature Ovarian Insufficiency (POI)

Interventions

Treatment group A:Femoston
Treatment group B:Bushen Ningxin Decoction
Treatment group C:Bushen Ningxin Decoction combined with Femoston

Sponsors

Affiliated Hospital of Nanjing University of Traditional Chinese Medicine, Jiangsu Provincial Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. Chinese women aged 20-40 years; 2. Meet the diagnostic criteria of Western medicine (POI); 3. Comply with the diagnosis standard of TCM syndrome differentiation (heart and kidney do not submit syndrome); 4. Meet the diagnostic criteria for circadian rhythm disorder sleep-wake disorder in the third edition of the National Classification of Sleep Disorders (ICSD-3); 5. No history of hormone drugs and drugs affecting glucose metabolism in the first 3 months of treatment; 6. Volunteer participation and informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with POI caused by bilateral ovarian resection, primary amenorrhea in puberty, combined with uterine or ovarian organic lesions, reproductive system or breast cancer; 2. Oligomenorrhea or amenorrhea caused by endocrine diseases such as polycystic ovary syndrome, adrenal hyperplasia, hyperprolactinemia, Sheehan syndrome; 3. POI manifested as premenstrual; 4. Congenital abnormal development of reproductive organs; 5. Patients with serious primary diseases such as liver and kidney system, cardiovascular or hematopoietic system; 6. Patients with mental illness; 7. Those with contraindications or allergies to hormone drugs; 8. Combined with other medical, neurological and mental diseases: abnormal thyroid function, dementia, Parkinson's syndrome, schizophrenia and other sleep disorders.

Design outcomes

Primary

MeasureTime frame
serum follicle-stimulating hormone level;ovulation rate;insomnia severity index;Pittsburgh Sleep Quality Index;total clinical response rate;

Secondary

MeasureTime frame
serum sex hormone level;inducible nitric oxide synthase;endothelin-1;serum inflammatory markers;ovarian arterial blood flow index;TCM symptom score;fatigue scale score;Hamilton Depression Scale Score;

Countries

China

Contacts

Public ContactMa Weirong

Affiliated Hospital of Nanjing University of Traditional Chinese Medicine, Jiangsu Provincial Hospital of Traditional Chinese Medicine

doctorma2012@126.com+86 13813370955

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026